COMP <GO>
DBD vs CAT // RETURN ON INVESTED CAPITAL (ROIC)
Diebold Nixdorf Incorporated (NYSE) VS. Caterpillar Inc. (NYSE) • 15-METRIC TALLY: DBD 4
— CAT 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: CAT
LAST: $59.14 (+1.84%) • MKT CAP: $1.99B
roic
11.50%
LAST: $647.39 (-9.25%) • MKT CAP: $297.59B
roic
21.15%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DBD VS. CAT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DBD | CAT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 25.30% | 82.20% | -56.90 | CAT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 11.50% | 21.15% | -9.65 | CAT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.6x | 20.9x | -10.26 | DBD | /valuation <GO> |
| Free Cash Flow Yield | 15.14% | 3.74% | +11.40 | DBD | /fcf-yield <GO> |
| Operating Margin | 6.40% | 17.52% | -11.12 | CAT | /operating-margins <GO> |
| Net Profit Margin | 2.50% | 14.51% | -12.01 | CAT | /net-margins <GO> |
| Revenue Growth (YoY) | 1.50% | 18.36% | -16.86 | CAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.05% | -1.05 | CAT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.79 | 4.34 | -2.55 | CAT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | DBD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 8.46% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.7 | 33.5 | -5.82 | CAT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.02 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.5x | 26.0x | -6.46 | DBD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.99B | $297.59B | -$295.60B | CAT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DBD REV | CAT REV | DBD GROSS % | CAT GROSS % | DBD FCF | CAT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.81B | $67.59B | 25.3% | 99.9% | $300.7M | $8.92B |
| FY 2024 | $3.75B | $64.81B | 24.5% | 100.0% | $149.2M | $10.05B |
| FY 2023 | — | $67.06B | — | 99.8% | — | $11.29B |
| FY 2022 | — | $59.43B | — | 99.3% | — | $6.47B |
| FY 2021 | — | $50.97B | — | 30.3% | — | $6.11B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DBD // BETA —
CAT // BETA 1.02